On 6 December 2019, Kuros Biosciences, a life science company focusing

on the development and marketing of orthobiologics, completed a capital

increase by way of a rights offering to its shareholders. 36.3% of the

shareholders of Kuros Biosciences exercised their subscription rights in the

rights offering. 2,818,718 of the remaining shares not subscribed were

preferably allocated to Optiverder B.V. and further remaining shares were

placed in the market. The offer price was set at CHF 1.95 per share.

Octavian and Helvetische Bank acted as Managers.

Bär & Karrer acted as legal adviser to the Managers in this

transaction. The team included Thomas U. Reutter, Alexander von Jeinsen and

Carlo Hunter (all Capital Markets) as well as Christoph Suter and Martin Leu

(both Tax).